DACTINOMYCIN

First approved in 1964

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C62H86N12O16
Molecular Weight	1255.4194
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C3=C4N=C5C(OC4=C(C)C=C3)=C(C)C(=O)C(N)=C5C(=O)N[C@H]6[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]7([H])CCCN7C(=O)[C@H](NC6=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C

InChI

InChIKey=RJURFGZVJUQBHK-IIXSONLDSA-N

InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C62H86N12O16
Molecular Weight	1255.4194
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1734954

Dactinomycin (actinomycin D) was isolated from Streptomyces by Selman Waksman in 1940s. The antibiotic shows anti-cancer activity; it was approved by FDA for the treatment of different cancer conditions among which are Ewing's sarcoma, Wilm's tumor, gestational trophoblastic disease, etc. Dactinomycin exerts its action by binding to DNA (preferably to GC motif) and thus inhibiting transcription.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 282 Target ID: CHEMBL2311221 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Binding Agent 1076		156.25 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Wilms' tumor 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8583	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Childhood rhabdomyosarcoma 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8583	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Metastatic nonseminomatous testicular cancer 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8583	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Ewing’s sarcoma 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8583	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Gestational trophoblastic neoplasia 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Primary	Approved 8583	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Locally recurrent and locoregional sarcomas 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Palliative	Approved 8583	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Locally recurrent and locoregional carcinomas 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Palliative	Approved 8583	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964
Locally recurrent and locoregional adenocarcinomas 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf	Palliative	Approved 8583	COSMEGEN Approved Use COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date 1964

C_max

Value	Dose	Co-administered	Analyte	Population
30.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
35.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931/	1.5 mg/m² 1 times / day steady-state, intravenous dose: 1.5 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: UNHEALTHY age: sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
142.4 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	DACTINOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3.62 mg × min/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931/	1.5 mg/m² 1 times / day steady-state, intravenous dose: 1.5 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DACTINOMYCIN plasma	Homo sapiens population: UNHEALTHY age: sex: FEMALE / MALE food status: UNKNOWN
12.8 mg × min/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24968986/	1.5 mg/m² 1 times / day multiple, intravenous dose: 1.5 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered:	DACTINOMYCIN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
28.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931/	1.5 mg/m² 1 times / day steady-state, intravenous dose: 1.5 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: UNHEALTHY age: sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253	3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		DACTINOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months Health Status: unhealthy Age Group: 18 months Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	Other AEs: Pancytopenia, Mucositis... Other AEs: Pancytopenia (1 patient) Mucositis (severe, 1 patient) Pancreatitis (1 patient) Hyponatremia (1 patient) Hypocalcemia (1 patient) Respiratory distress (1 patient) Melena (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
0.15 ug/kg multiple, intravenous Highest studied dose Dose: 0.15 ug/kg Route: intravenous Route: multiple Dose: 0.15 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/1139861	unhealthy, 40-77 years Health Status: unhealthy Age Group: 40-77 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1139861	Sources: https://pubmed.ncbi.nlm.nih.gov/1139861
1.5 mg/m2 single, intravenous Highest studied dose Dose: 1.5 mg/m2 Route: intravenous Route: single Dose: 1.5 mg/m2 Sources: https://pubmed.ncbi.nlm.nih.gov/14522028	unknown, children Health Status: unknown Age Group: children Sources: https://pubmed.ncbi.nlm.nih.gov/14522028	Sources: https://pubmed.ncbi.nlm.nih.gov/14522028

AEs

AE	Significance	Dose	Population
Hypocalcemia	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months Health Status: unhealthy Age Group: 18 months Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Hyponatremia	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months Health Status: unhealthy Age Group: 18 months Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Melena	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months Health Status: unhealthy Age Group: 18 months Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Pancreatitis	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months Health Status: unhealthy Age Group: 18 months Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Pancytopenia	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months Health Status: unhealthy Age Group: 18 months Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Respiratory distress	1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months Health Status: unhealthy Age Group: 18 months Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/10531579
Mucositis	severe, 1 patient	0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10531579	unhealthy, 18 months Health Status: unhealthy Age Group: 18 months Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/10531579

Sourcing

Vendor/Aggregator	ID	URL
abcr GmbH	AB353527	http://www.abcr.de/shop/en/AB353527
Achemtek	0104-058162	http://www.achemtek.com/50-76-0
Acorn PharmaTech	ACN-036884	http://www.acornpharmatech.com/
Ambinter	Amb19930304	http://www.ambinter.com/reference/19930304
Aurora Fine Chemicals LLC	A17.878.164	http://online.aurorafinechemicals.com/info?ID=A17.878.164
AvaChem Scientific	4693	http://www.avachem.com/productSearch.asp?4693
Avantor Inc	101096-738	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101096-738
Avantor Inc	200036-466	https://us.vwr.com/store/product/18601366/actinomycin-d
BOC Sciences	50-76-0	https://adc.bocsci.com/product/actinomycin-d-cas-50-76-0-1293.html
Chemspace	CSSB02125550997	https://chem-space.com/CSSB02125550997
eNovation Chemicals	D371034	http://www.enovationchem.com/productDetails.asp?productID=D371034
Glentham Life Sciences	GA0481	http://www.glentham.com/products/product/GA0481/
iChemical	EBD32182	http://www.ichemical.com/products/50-76-0.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
OChem	10380	http://www.ocheminc.com/index.php?act=psearch&pid=050A760
Selleck Chemicals	S8964	http://www.selleckchem.com/products/actinomycin-d.html
Sigma-Aldrich	01815_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/01815?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1162400_USP	https://www.sigmaaldrich.com/catalog/product/usp/1162400?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A1410_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a1410?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A4262_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a4262?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A9415_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/a9415?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S548606	http://www.smolecule.com/products/s548606
THE BioTek	bt-288011	https://www.thebiotek.com/product/inhibitors/bt-288011
VladaChem	VL272217-10MG	https://www.vladachem.com/product.php?products=50-76-0

PubMed

Title	Date	PubMed
Promoting insulin secretion in pancreatic islets by means of bisphenol A and nonylphenol via intracellular estrogen receptors.	2005-05	15778011
Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.	2005-04	15725475
Mitochondrial redox state regulates transcription of the nuclear-encoded mitochondrial protein manganese superoxide dismutase: a proposed adaptive response to mitochondrial redox imbalance.	2005-03-01	15683720
Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression.	2005-03	15701621
Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells.	2005-02-25	15652504
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells.	2005-02-10	15592511
Heme oxygenase-1-mediated partial cytoprotective effect by NO on cadmium-induced cytotoxicity in C6 rat glioma cells.	2005-02	15582353
Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists.	2005-01-28	15531761
Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver.	2005-01-14	15537571
Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells.	2005-01-01	15588712
Coordinated secretion of alkaline phosphatase into serum and intestine in fat-fed rats.	2004-12-16	15599000
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.	2004-12-01	15572759
Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes.	2004-12	15610522
Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma.	2004-12	15591910
Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues.	2004-11	15543019
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism.	2004-11	15314095
2-Substituted benzoxazinone analogues as anti-human coronavirus (anti-HCoV) and ICAM-1 expression inhibition agents.	2004-09-20	15324901
Catecholamine effects on human melanoma cells evoked by alpha1-adrenoceptors.	2004-08	15278367
Mechanism of heme oxygenase-1 gene induction by quercetin in rat aortic smooth muscle cells.	2004-06	15118350
Induction of manganese-superoxide dismutase by YS 51, a synthetic 1-(beta-naphtylmethyl)6,7-dihydroxy- 1,2,3,4-tetrahydroisoquinoline alkaloid: implication for anti-inflammatory actions.	2004-06	15118344
Overexpression of phospholipase D prevents actinomycin D-induced apoptosis through potentiation of phosphoinositide 3-kinase signalling pathways in Chinese-hamster ovary cells.	2004-03-01	14640974
Endosulfan-mediated biochemical changes in the freshwater fish Clarias batrachus.	2004-03	15202864
Dactinomycin-induced veno-occlusive disease in rats. The hepatoprotective action of amifostine. Evaluation in a light and electron microscope.	2004-02	15039909
Quercetin enhances melanogenesis by increasing the activity and synthesis of tyrosinase in human melanoma cells and in normal human melanocytes.	2004-02	14717847
DEP-induced fra-1 expression correlates with a distinct activation of AP-1-dependent gene transcription in the lung.	2004-02	14565943
Cytoprotective effects of heme oxygenase-1 induction by 3-O-caffeoyl-1-methylquinic acid.	2004-01-01	14732289
Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells.	2003-12-20	14601052
Identification of manganese superoxide dismutase as a NO-regulated gene in rat glomerular mesangial cells by 2D gel electrophoresis.	2003-12	14996425
Zinc modulates mRNA levels of cytokines.	2003-11	12812920
Effects of hypoxia on monocyte inflammatory mediator production: Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis.	2003-10-03	12874281
The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.	2003-10	12869419
Morphine suppresses lymphocyte apoptosis by blocking p53-mediated death signaling.	2003-09-05	12927789
Thyroid hormone activates fibroblast growth factor receptor-1 in bone.	2003-09	12805413
An efficient, nonenzymatic method for isolation and culture of murine aortic endothelial cells and their response to inflammatory stimuli.	2003-08-02	12892526
Induction of 1-cys peroxiredoxin expression by oxidative stress in lung epithelial cells.	2003-08	12851211
Regulation of rat intestinal GLUT2 mRNA abundance by luminal and systemic factors.	2003-06-10	12787936
Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.	2003-06	12807743
Interplay between transcriptional and post-transcriptional regulation of Cyp2a5 expression.	2003-05-15	12754101
Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells.	2003-05-15	12704794
Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases.	2003-05	12748258
Differential effects of thyroxine on metabolic enzymes and other macromolecules in a freshwater teleost.	2003-04-01	12658717
Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation.	2003-03-15	12479793
Synergy between sulforaphane and selenium in the induction of thioredoxin reductase 1 requires both transcriptional and translational modulation.	2003-03	12663510
Differential expression of c-fos and c-myc protooncogenes by estrogens, xenobiotics and other growth-stimulatory agents in primary rat hepatocytes.	2003-03	12632255
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.	2002-12-01	12430140
Interleukin 1beta induces functional prostaglandin E synthase in cultured human umbilical vein endothelial cells.	2002-12	12512699
Phospholipase D activation by sphingosine 1-phosphate regulates interleukin-8 secretion in human bronchial epithelial cells.	2002-08-16	12039947
Induction and superinduction of 2,3,7,8-tetrachlorodibenzo-rho-dioxin-inducible poly(ADP-ribose) polymerase: role of the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator transcription activation domains and a labile transcription repressor.	2002-08-15	12147270
Functional analysis of MRP1 cloned from bovine.	2002-06-19	12067707
[Veno-occlusive disease of the liver as a treatment complication in children with Wilm's tumor].	1992	1318536

Patents

Sample Use Guides

In Vivo Use Guide

Wilms’ Tumor, Childhood Rhabdomyosarcoma and Ewing’s Sarcoma: Regimens of 15 mcg/kg intravenously daily for five days administered in various combinations and schedules with other chemotherapeutic agents; Metastatic Nonseminomatous Testicular Cancer: 1000 mcg/m2 intravenously on Day 1 as part of a combination regimen with cyclophosphamide, bleomycin, vinblastine, and cisplatin; Gestational Trophoblastic Neoplasia: 12 mcg/kg intravenously daily for five days as a single agent. 500 mcg intravenously on Days 1 and 2 as part of a combination regimen with etoposide, methotrexate, folinic acid, vincristine, cyclophosphamide and cisplatin; Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies: 50 mcg (0.05 mg) per kilogram of body weight for lower extremity or pelvis, 35 mcg (0.035 mg) per kilogram of body weight for upper extremity.

Route of Administration: Intravenous

In Vitro Use Guide

Human osteosarcoma cell line MG63 were incubated with dactinomycin (actinomycin D) at final concentrations of 0.1, 0.5, 1 and 5 uM during 0, 2, 6 and 24 hours. The drug was shown to inhibit the proliferation of cells by decreasing cyclin gene transcriptions.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:33:17 GMT 2025` Edited by `admin` on `Wed Apr 02 07:33:17 GMT 2025`
Record UNII	1CC1JFE158
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

Actinomycin D

Preferred Name

English

DACTINOMYCIN

Official Name

English

DACTINOMYCIN [HSDB]

Common Name

English

ACTINOMYCIN C1

Common Name

English

ACTINOMYCIN D [WHO-IP]

Common Name

English

DACTINOMYCIN [WHO-IP]

Common Name

English

3H-PHENOXAZINE-1,9-DICARBOXAMIDE, 2-AMINO-N,N'-BIS(HEXADECAHYDRO-6,13-DIISOPROPYL-2,5,9-TRIMETHYL-1,4,7,11,14-PENTAOXO-1H-PYRROLO(2,1-I)(1,4,7,10,13)OXATETRAAZACYCLOHEXADECIN-10-YL)-4,6-DIMETHYL-3-OXO-

Common Name

English

ACTINOMYCIN-D

Common Name

English

ACTINOMYCIN I1

Common Name

English

DILACTONE ACTINOMYCIN D ACID

Common Name

English

ACTINOMYCIN D [JAN]

Common Name

English

DACTINOMYCIN [USP-RS]

Common Name

English

GNF-PF-2290

Code

English

DACTINOMYCIN [USP MONOGRAPH]

Common Name

English

ACTINOMYCIN D [IARC]

Common Name

English

DACTINOMYCIN [MART.]

Common Name

English

DACTINOMYCIN [USAN]

Common Name

English

DACTINOMYCIN [VANDF]

Common Name

English

MERACTINOMYCIN

Common Name

English

Dactinomycin [WHO-DD]

Common Name

English

ACTINOMYCIN X1

Common Name

English

DACTINOMYCINUM [WHO-IP LATIN]

Common Name

English

DACTINOMYCIN [MI]

Common Name

English

DACTINOMYCIN [ORANGE BOOK]

Common Name

English

N,N'-((2-AMINO-4,6-DIMETHYL-3-OXO-3H-PHENOXAZINE-1,9-DIYL)-BIS(CARBONYLIMINO(2-HYDROXYPROPYLIDENE)CARBONYLIMINOISOBUTYLIDENECARBONYL-1,2-PYRROLIDINEDIYLCARBONYL(METHYLIMINO)METHYLENECARBONYL))BIS(N-METHYL-L-VALINE) DILACTONE

Common Name

English

NSC-3053

Code

English

NCI-C04682

Code

English

ACTINOMYCIN IV

Common Name

English

dactinomycin [INN]

Common Name

English

ONCOSTATIN K

Common Name

English

COSMEGEN

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C204